Results 151 to 160 of about 13,730,156 (351)
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Molecular Oncology, EarlyView.RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
Institutional change and healthcare organizations: from professional dominance to managed care
International Journal of Integrated Care, 2002 Donald W. Light
doaj +3 more sources
The Chemistry of Light and Photography in their Application to Art, Science, and Industry [PDF]
, 1876 R. J. FRISWELL
openalex +1 more source
Designing at the End of the World [PDF]
, 2019 Fritsch, Jonas, Light, Ann, Loi, Daria
core +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Influence of Selective Light Scattering on Measurements of Absorption Spectra of Chlorella.
, 1959 Paul Latimer
openalex +2 more sources